{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:19:12Z","timestamp":1787926752015,"version":"build-2784847793"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Multisystem Inflammatory Syndrome in Children (MIS-C) is a severe post-COVID-19 complication characterized by hyperimmune activation and systemic inflammation. Identifying biomarkers for disease severity and predicting ICU admission is critical.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study analyzed 92 inflammatory biomarkers in serum samples from 22 pediatric MIS-C patients and 17 convalescent COVID-19 children using Olink proteomics. MIS-C samples were taken at diagnosis, before treatment, and at follow-up. Convalescent COVID-19 samples were taken 3 to 5 weeks after acute COVID-19 diagnosis, at a similar time to MIS-C theoretical occurrence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study identified 29 significantly altered biomarkers in MIS-C, including elevated pro-inflammatory cytokines (IFN-\u03b3, IL-6, TNF, IL-18), chemokines (CXCL9, CXCL10, CXCL11), and immune regulators (IL-10, PD-L1, CDCP1). Among these, random forest analysis highlighted 18 key markers distinguishing MIS-C from convalescent cases. ICU-admitted MIS-C patients displayed distinct biomarker signatures, and the differential regulation of IL-2, IL-33, CD244, SCF, TNFRSF9, and CD8\u03b1, was sufficient to predict almost all ICU admissions. Notably, lower levels of soluble CD244 and TNFRSF9 correlated with longer hospital stays. Finally, longitudinal analysis showed biomarker normalization within two months post-MIS-C.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides a detailed characterization of the MIS-C inflammatory response, identifying potential biomarkers for improved early diagnosis and clinical management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impact<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>MIS-C incidence has substantially decreased since the beginning of the COVID-19 pandemic, but rare cases are still occurring with severe to critical presentation.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>We identified 6 biomarkers, IL-2, IL-33, CD244, SCF, TNFRSF9, and CD8\u03b1, predictors of ICU-admission in MIS-C.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>We showed the normalization of cytokine profiles by 2 months following treatment in MIS-C.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>This study Identified potential biomarkers for improved early diagnosis and clinical management of MIS-C.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41390-025-04542-8","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T15:12:06Z","timestamp":1761923526000},"page":"420-430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tracking the soluble biomarkers of MIS-C and their association with clinical parameters and severity"],"prefix":"10.1038","volume":"100","author":[{"given":"Tetyana","family":"Pidkova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Pino-Ramirez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Urrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Aguilar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Moncunill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonaventura","family":"Clotet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlota","family":"Doba\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Fortuny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e0","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Trinit\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"4542_CR1","doi-asserted-by":"publisher","unstructured":"Viner, R. M. et al. Systematic review of reviews of symptoms and signs of COVID-19 in children and adolescents. Arch. Dis. Childhood 106, 802\u2013807 (2021). https:\/\/doi.org\/10.1136\/archdischild-2020-320972.","DOI":"10.1136\/archdischild-2020-320972"},{"key":"4542_CR2","doi-asserted-by":"publisher","unstructured":"Parri, N. et al. Characteristic of COVID-19 infection in pediatric patients: early findings from two Italian Pediatric Research Networks. https:\/\/doi.org\/10.1007\/s00431-020-03683-8.","DOI":"10.1007\/s00431-020-03683-8"},{"key":"4542_CR3","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s00431-023-04862-z","volume":"182","author":"R Pino","year":"2023","unstructured":"Pino, R. et al. Multisystem inflammatory syndrome in children and SARS-CoV-2 variants: a two-year ambispective multicentric cohort study in Catalonia, Spain. Eur. J. Pediatr. 182, 1897 (2023).","journal-title":"Eur. J. Pediatr."},{"key":"4542_CR4","unstructured":"Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. https:\/\/www.who.int\/news-room\/commentaries\/detail\/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19."},{"key":"4542_CR5","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.15585\/mmwr.mm705152a3","volume":"70","author":"V Wanga","year":"2021","unstructured":"Wanga, V. et al. Characteristics and clinical outcomes of children and adolescents aged <18 years hospitalized with COVID-19 \u2014 Six Hospitals, United States, July\u2013August 2021. Morbid. Mortal. Wkly. Rep. 70, 1766\u20131772 (2021).","journal-title":"Morbid. Mortal. Wkly. Rep."},{"key":"4542_CR6","doi-asserted-by":"publisher","first-page":"e2021053418","DOI":"10.1542\/peds.2021-053418","volume":"149","author":"RC Woodruff","year":"2021","unstructured":"Woodruff, R. C. et al. Risk Factors for Severe COVID-19 in Children. Pediatrics 149, e2021053418 (2021).","journal-title":"Pediatrics"},{"key":"4542_CR7","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1016\/S0140-6736(20)31094-1","volume":"395","author":"S Riphagen","year":"2020","unstructured":"Riphagen, S., Gomez, X., Gonzalez-Martinez, C., Wilkinson, N. & Theocharis, P. Hyperinflammatory shock in children during COVID-19 pandemic. Lancet 395, 1607\u20131608 (2020).","journal-title":"Lancet"},{"key":"4542_CR8","unstructured":"Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with SARS-CoV-2 Infection 2023 Case Definition | CDC. https:\/\/ndc.services.cdc.gov\/case-definitions\/multisystem-inflammatory-syndrome-in-children-mis-c-2023\/."},{"key":"4542_CR9","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1093\/jpids\/piab007","volume":"10","author":"BT Cirks","year":"2021","unstructured":"Cirks, B. T. et al. Sixteen Weeks Later: Expanding the Risk Period for Multisystem Inflammatory Syndrome in Children. J. Pediatr. Infect. Dis. Soc. 10, 686\u2013690 (2021).","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"4542_CR10","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1056\/NEJMoa2021680","volume":"383","author":"LR Feldstein","year":"2020","unstructured":"Feldstein, L. R. et al. Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. N. Engl. J. Med. 383, 334\u2013346 (2020).","journal-title":"N. Engl. J. Med."},{"key":"4542_CR11","doi-asserted-by":"publisher","unstructured":"Day-Lewis, M. et al. Updated case definition of MIS-C and implications for clinical care. Pediatrics https:\/\/doi.org\/10.1542\/peds.2023-063259 (2024).","DOI":"10.1542\/peds.2023-063259"},{"key":"4542_CR12","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S2352-4642(21)00050-X","volume":"5","author":"JY Abrams","year":"2021","unstructured":"Abrams, J. Y. et al. Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study. Lancet Child Adolesc. Health 5, 323\u2013331 (2021).","journal-title":"Lancet Child Adolesc. Health"},{"key":"4542_CR13","unstructured":"COVID-19: Multisystem inflammatory syndrome in children (MIS-C) management and outcome - UpToDate. https:\/\/www.uptodate.com\/contents\/covid-19-multisystem-inflammatory-syndrome-in-children-mis-c-management-and-outcome?search=diagnostic%20criteria%20for%20MIS-C%20to%20ICU%20admissions&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2."},{"key":"4542_CR14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1161\/CIRCULATIONAHA.120.048360","volume":"142","author":"Z Belhadjer","year":"2020","unstructured":"Belhadjer, Z. et al. Acute heart failure in multisystem inflammatory syndrome in children in the context of global SARS-CoV-2 pandemic. Circulation 142, 429\u2013436 (2020).","journal-title":"Circulation"},{"key":"4542_CR15","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jama.2021.0694","volume":"325","author":"N Ouldali","year":"2021","unstructured":"Ouldali, N. et al. Association of intravenous Immunoglobulins Plus Methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA 325, 855\u2013864 (2021).","journal-title":"JAMA"},{"key":"4542_CR16","first-page":"803","volume":"39","author":"AS Harahsheh","year":"2023","unstructured":"Harahsheh, A. S. et al. Management of multisystem inflammatory syndrome in children: decision-making regarding a new condition in the absence of clinical trial data. Can. J. Cardiol. 39, 803 (2023).","journal-title":"Can. J. Cardiol."},{"key":"4542_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S2352-4642(20)30304-7","volume":"5","author":"R Harwood","year":"2021","unstructured":"Harwood, R. et al. A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process. Lancet Child Adolesc. Health 5, 133 (2021).","journal-title":"Lancet Child Adolesc. Health"},{"key":"4542_CR18","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1111\/jth.15073","volume":"18","author":"NA Goldenberg","year":"2020","unstructured":"Goldenberg, N. A. et al. Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19\u2013related illness. J. Thromb. Haemost. 18, 3099\u20133105 (2020).","journal-title":"J. Thromb. Haemost."},{"key":"4542_CR19","doi-asserted-by":"crossref","unstructured":"Rybkina, K. et al. SARS-CoV-2 infection and recovery in children: Distinct T cell responses in MIS-C compared to COVID-19. J. Exp. Med. 220, e20221518 (2023).","DOI":"10.1084\/jem.20221518"},{"key":"4542_CR20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s00246-022-03052-2","volume":"44","author":"J Yasuhara","year":"2023","unstructured":"Yasuhara, J. et al. Longitudinal cardiac outcomes of multisystem inflammatory syndrome in children: a systematic review and meta-analysis. Pediatr. Cardiol. 44, 892\u2013907 (2023).","journal-title":"Pediatr. Cardiol."},{"key":"4542_CR21","doi-asserted-by":"publisher","first-page":"1080654","DOI":"10.3389\/fped.2022.1080654","volume":"10","author":"G Zuccotti","year":"2023","unstructured":"Zuccotti, G. et al. Six-month multidisciplinary follow-up in multisystem inflammatory syndrome in children: An Italian single-center experience. Front. Pediatr. 10, 1080654 (2023).","journal-title":"Front. Pediatr."},{"key":"4542_CR22","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1161\/CIR.0000000000001295","volume":"150","author":"PN Jone","year":"2024","unstructured":"Jone, P. N. et al. Update on diagnosis and management of Kawasaki Disease: A scientific statement from the American Heart Association. Circulation 150, e481\u2013e500 (2024).","journal-title":"Circulation"},{"key":"4542_CR23","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/art.39332","volume":"68","author":"A Ravelli","year":"2016","unstructured":"Ravelli, A. et al. 2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism\/American College of Rheumatology\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 68, 566\u2013576 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"4542_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.3390\/children7070069","volume":"7","author":"NA Nakra","year":"2020","unstructured":"Nakra, N. A., Blumberg, D. A., Herrera-Guerra, A. & Lakshminrusimha, S. Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of clinical presentation, hypothetical pathogenesis, and proposed management. Children 7, 69 (2020).","journal-title":"Children"},{"key":"4542_CR25","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.cell.2020.09.034","volume":"183","author":"CN Gruber","year":"2020","unstructured":"Gruber, C. N. et al. Mapping Systemic inflammation and antibody responses in multisystem inflammatory Syndrome in Children (MIS-C). Cell 183, 982\u2013995.e14 (2020).","journal-title":"Cell"},{"key":"4542_CR26","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/s41591-022-01724-3","volume":"28","author":"K Sacco","year":"2022","unstructured":"Sacco, K. et al. Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19. Nat. Med. 28, 1050\u20131062 (2022).","journal-title":"Nat. Med"},{"key":"4542_CR27","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/INF.0000000000004267","volume":"43","author":"S Yeoh","year":"2024","unstructured":"Yeoh, S. et al. Plasma protein biomarkers distinguish multisystem inflammatory syndrome in children from other pediatric infectious and inflammatory diseases. Pediatr. Infect. Dis. J. 43, 444\u2013453 (2024).","journal-title":"Pediatr. Infect. Dis. J."},{"key":"4542_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-66891-4","volume":"14","author":"DM Tran","year":"2024","unstructured":"Tran, D. M. et al. Severity predictors for multisystemic inflammatory syndrome in children after SARS-CoV-2 infection in Vietnam. Sci. Rep. 14, 1\u201310 (2024).","journal-title":"Sci. Rep."},{"key":"4542_CR29","doi-asserted-by":"publisher","first-page":"10435","DOI":"10.12998\/wjcc.v10.i29.10435","volume":"10","author":"M Rodriguez-Gonzalez","year":"2022","unstructured":"Rodriguez-Gonzalez, M. & Castellano-Martinez, A. Age-adjusted NT-proBNP could help in the early identification and follow-up of children at risk for severe multisystem inflammatory syndrome associated with COVID-19 (MIS-C). World J. Clin. Cases 10, 10435\u201310450 (2022).","journal-title":"World J. Clin. Cases"},{"key":"4542_CR30","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.cell.2020.09.016","volume":"183","author":"CR Consiglio","year":"2020","unstructured":"Consiglio, C. R. et al. The immunology of multisystem inflammatory syndrome in children with COVID-19. Cell 183, 968\u2013981.e7 (2020).","journal-title":"Cell"},{"key":"4542_CR31","doi-asserted-by":"publisher","first-page":"110237","DOI":"10.1016\/j.clim.2024.110237","volume":"264","author":"A Reiter","year":"2024","unstructured":"Reiter, A. et al. Proteomic mapping identifies serum marker signatures associated with MIS-C-specific hyperinflammation and cardiovascular manifestation. Clin. Immunol. 264, 110237 (2024).","journal-title":"Clin. Immunol."},{"key":"4542_CR32","doi-asserted-by":"publisher","first-page":"110252","DOI":"10.1016\/j.clim.2024.110252","volume":"264","author":"AJ Tulling","year":"2024","unstructured":"Tulling, A. J. et al. Serum proteomics reveals hemophagocytic lymphohistiocytosis-like phenotype in a subset of patients with multisystem inflammatory syndrome in children. Clin. Immunol. 264, 110252 (2024).","journal-title":"Clin. Immunol."},{"key":"4542_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27544-6","volume":"12","author":"C Diorio","year":"2021","unstructured":"Diorio, C. et al. Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction. Nat. Commun. 12, 7222 (2021).","journal-title":"Nat. Commun."},{"key":"4542_CR34","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41390-022-02029-4","volume":"92","author":"SL Gurlevik","year":"2022","unstructured":"Gurlevik, S. L. et al. The difference of the inflammatory milieu in MIS-C and severe COVID-19. Pediatr. Res. 92, 1805 (2022).","journal-title":"Pediatr. Res."},{"key":"4542_CR35","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.cyto.2018.05.029","volume":"111","author":"A Chalin","year":"2018","unstructured":"Chalin, A. et al. Serum CXCL10, CXCL11, CXCL12, and CXCL14 chemokine patterns in patients with acute liver injury. Cytokine 111, 500\u2013504 (2018).","journal-title":"Cytokine"},{"key":"4542_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.21037\/dmr-21-87","volume":"5","author":"KL Poulsen","year":"2022","unstructured":"Poulsen, K. L., Ross, C. K. C.-D., Chaney, J. K. & Nagy, L. E. Role of the chemokine system in liver fibrosis: a narrative review. Dig. Med. Res. 5, 30\u201330 (2022).","journal-title":"Dig. Med. Res."},{"key":"4542_CR37","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s12265-016-9703-3","volume":"9","author":"R Altara","year":"2016","unstructured":"Altara, R. et al. CXCL10 is a circulating inflammatory marker in patients with advanced heart failure: a pilot study. J. Cardiovasc Transl. Res. 9, 302\u2013314 (2016).","journal-title":"J. Cardiovasc Transl. Res"},{"key":"4542_CR38","doi-asserted-by":"publisher","first-page":"e0141394","DOI":"10.1371\/journal.pone.0141394","volume":"10","author":"R Altara","year":"2015","unstructured":"Altara, R. et al. Left ventricular dysfunction and CXCR3 ligands in hypertension: from animal experiments to a population-based pilot study. PLoS One 10, e0141394 (2015).","journal-title":"PLoS One"},{"key":"4542_CR39","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.3390\/ijms23073673","volume":"23","author":"M Gudowska-Sawczuk","year":"2022","unstructured":"Gudowska-Sawczuk, M. & Mroczko, B. What Is Currently Known about the Role of CXCL10 in SARS-CoV-2 Infection?. Int. J. Mol. Sci. 23, 3673 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"4542_CR40","doi-asserted-by":"publisher","first-page":"44.25","DOI":"10.4049\/jimmunol.188.Supp.44.25","volume":"188","author":"O Allam","year":"2012","unstructured":"Allam, O., Samarani, S., Marzouk, R. & Ahmad, A. Human platelets produce and constitute the main source of IL-18 in the circulation (44.25). J. Immunol. 188, 44.25\u201344.25 (2012).","journal-title":"J. Immunol."},{"key":"4542_CR41","first-page":"1251","volume":"19","author":"M Zhu","year":"2019","unstructured":"Zhu, M., Rong, X., Li, M. & Wang, S. IL-18 and IL-35 in the serum of patients with sepsis thrombocytopenia and the clinical significance. Exp. Ther. Med. 19, 1251 (2019).","journal-title":"Exp. Ther. Med."},{"key":"4542_CR42","doi-asserted-by":"crossref","unstructured":"Esteve-Sole, A. et al. Similarities and differences between the immunopathogenesis of COVID-19\u2013related pediatric multisystem inflammatory syndrome and Kawasaki disease. J. Clin. Invest. 131, e144554 (2021).","DOI":"10.1172\/JCI144554"},{"key":"4542_CR43","doi-asserted-by":"publisher","first-page":"981711","DOI":"10.3389\/fped.2022.981711","volume":"10","author":"P Buda","year":"2022","unstructured":"Buda, P. et al. Clinical characteristics of children with MIS-C fulfilling classification criteria for macrophage activation syndrome. Front. Pediatr. 10, 981711 (2022).","journal-title":"Front. Pediatr."},{"key":"4542_CR44","doi-asserted-by":"publisher","first-page":"e574","DOI":"10.1016\/S2665-9913(21)00139-9","volume":"3","author":"JJ Rodriguez-Smith","year":"2021","unstructured":"Rodriguez-Smith, J. J. et al. Inflammatory biomarkers in COVID-19-associated multisystem inflammatory syndrome in children, Kawasaki disease, and macrophage activation syndrome: a cohort study. Lancet Rheumatol. 3, e574\u2013e584 (2021).","journal-title":"Lancet Rheumatol."},{"key":"4542_CR45","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/CCM.0000000000005361","volume":"50","author":"MR Hines","year":"2022","unstructured":"Hines, M. R. et al. Consensus-Based Guidelines for the Recognition, Diagnosis, and Management of Hemophagocytic Lymphohistiocytosis in Critically Ill Children and Adults. Crit. Care Med. 50, 860\u2013872 (2022).","journal-title":"Crit. Care Med."},{"key":"4542_CR46","doi-asserted-by":"crossref","unstructured":"Le Marchand, C. et al. Multisystem inflammatory syndrome in children (MIS-C) cases by vaccination status in California. Vaccine 43, 126499 (2025).","DOI":"10.1016\/j.vaccine.2024.126499"},{"key":"4542_CR47","doi-asserted-by":"publisher","first-page":"e003532","DOI":"10.1136\/jitc-2021-003532","volume":"10","author":"J Glez-Vaz","year":"2022","unstructured":"Glez-Vaz, J. et al. Soluble CD137 as a dynamic biomarker to monitor agonist CD137 immunotherapies. J. Immunother. Cancer 10,\u00a0e003532 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"4542_CR48","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.4049\/jimmunol.142.7.2230","volume":"142","author":"BE Tomkinson","year":"1989","unstructured":"Tomkinson, B. E., Brown, M. C., Ip, S. H., Carrabis, S. & Sullivan, J. L. Soluble CD8 during T cell activation. J. Immunol. 142, 2230\u20132236 (1989).","journal-title":"J. Immunol."},{"key":"4542_CR49","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jaut.2013.09.002","volume":"47","author":"K Kachapati","year":"2013","unstructured":"Kachapati, K. et al. Recombinant soluble CD137 prevents type one diabetes in nonobese diabetic mice. J. Autoimmun. 47, 94\u2013103 (2013).","journal-title":"J. Autoimmun."},{"key":"4542_CR50","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0198-8859(99)00014-2","volume":"60","author":"CL Morgan","year":"1999","unstructured":"Morgan, C. L., Price, C. P., Cohen, S. B. A., Madrigal, J. A. & Newman, D. J. Soluble CD8 stabilizes the HLA class I molecule by promoting \u03b22M exchange: Analysis in real-time. Hum. Immunol. 60, 442\u2013449 (1999).","journal-title":"Hum. Immunol."},{"key":"4542_CR51","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.imlet.2022.07.003","volume":"248","author":"MO de Marques","year":"2022","unstructured":"de Marques, M. O. et al. Soluble CD137 as a potential biomarker for severe COVID-19. Immunol. Lett. 248, 119 (2022).","journal-title":"Immunol. Lett."},{"key":"4542_CR52","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/s41590-023-01697-6","volume":"25","author":"TM Brunner","year":"2024","unstructured":"Brunner, T. M. et al. A type 1 immunity-restricted promoter of the IL\u221233 receptor gene directs antiviral T-cell responses. Nat. Immunol. 25, 256\u2013267 (2024).","journal-title":"Nat. Immunol."},{"key":"4542_CR53","doi-asserted-by":"publisher","first-page":"110117","DOI":"10.1016\/j.isci.2024.110117","volume":"27","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. The alarmin IL-33 exacerbates pulmonary inflammation and immune dysfunction in SARS-CoV-2 infection. iScience 27, 110117 (2024).","journal-title":"iScience"},{"key":"4542_CR54","doi-asserted-by":"publisher","first-page":"E1520","DOI":"10.1073\/pnas.1710401115","volume":"115","author":"AE Russi","year":"2018","unstructured":"Russi, A. E., Ebel, M. E., Yang, Y. & Brown, M. A. Male-specific IL-33 expression regulates sex-dimorphic EAE susceptibility. Proc. Natl. Acad. Sci. USA 115, E1520\u2013E1529 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"4542_CR55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jpeds.2021.06.002","volume":"237","author":"RL DeBiasi","year":"2021","unstructured":"DeBiasi, R. L. et al. Multisystem Inflammatory Syndrome of Children: Subphenotypes, Risk Factors, Biomarkers, Cytokine Profiles, and Viral Sequencing. J. Pediatr. 237, 125\u2013135.e18 (2021).","journal-title":"J. Pediatr."},{"key":"4542_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-024-52246-0","volume":"15","author":"H Patel","year":"2024","unstructured":"Patel, H. et al. Shared neutrophil and T cell dysfunction is accompanied by a distinct interferon signature during severe febrile illnesses in children. Nat. Commun. 15, 1\u201316 (2024).","journal-title":"Nat. Commun."},{"key":"4542_CR57","doi-asserted-by":"publisher","first-page":"100443","DOI":"10.1016\/j.lanepe.2022.100443","volume":"19","author":"S Rhedin","year":"2022","unstructured":"Rhedin, S. et al. Risk factors for multisystem inflammatory syndrome in children \u2013 A population-based cohort study of over 2 million children. Lancet Reg. Health - Eur. 19, 100443 (2022).","journal-title":"Lancet Reg. Health - Eur."},{"key":"4542_CR58","doi-asserted-by":"publisher","unstructured":"Beth, M., Son, F., Burns, J. C. & Newburger, J. W. A new definition for multisystem inflammatory syndrome in children. https:\/\/doi.org\/10.1542\/peds.2022-060302 (2023).","DOI":"10.1542\/peds.2022-060302"},{"key":"4542_CR59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa2102968","volume":"385","author":"AJ McArdle","year":"2021","unstructured":"McArdle, A. J. et al. Treatment of multisystem inflammatory syndrome in children. N. Engl. J. Med. 385, 11\u201322 (2021).","journal-title":"N. Engl. J. Med."}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04542-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04542-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04542-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T13:20:40Z","timestamp":1787923240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04542-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["4542"],"URL":"https:\/\/doi.org\/10.1038\/s41390-025-04542-8","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have declared that no conflict of interest exists. Unrelated to this work, J.B. has received institutional funding from Gr\u00edfols, Nesapor Europe, HIPRA, and MSD. J.B. received honoraria from Nesapor Europe and HIPRA.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Blood Plasma samples of the participants were taken after written informed consent in Hospital Sant Joan de D\u00e9u, Universitat de Barcelona (Spain).","order":2,"name":"Ethics","label":"Consent statement","group":{"name":"EthicsHeading","label":"Ethics"}}]}}